Table 6.
Summary of p53-R175H gain-of-function of promoting tumor drug-resistance, inflammation, angiogenesis, and metabolic reprogramming.
| Gain-of-Function | Tumor Type | Same Function Mutations |
R175H Interacting Protein |
Affected Downstream Molecule or Pathway | Ref. |
|---|---|---|---|---|---|
| Chemoresistance | Colorectal cancer | R273H, R248W | NF-Y, p300 | Ephrin-B2/SRC/FAK/ MEKK/MEK/JNK/c-JUN/ABCG |
[63] |
| Lung cancer | R273H, D281G | - | NF-κB2 | [59] | |
| Lung cancer | - | - | miR128-2/E2F5/p21/pro-caspase-3 | [60] | |
| Breast, colorectal, head and neck, and lung cancer | R248W, R273H, R280K, R282W | SMDA3 | REGγ/proteasome activation/p53, p21, and p16 degradation |
[61] | |
| Breast and lung cancer | G245A, D281G, R273H, R280K | - | SLC25A1 | [62] | |
| Angiogenesis | Breast cancer | R273H, R280K | E2F1 | ID4/IL8, GRO-α | [64] |
| Inflammatory response |
Colorectal cancer | R273H | - |
NF-κB expression in response to TNFα |
[66] |
| Breast, colorectal, and liver cancer |
R273H, R280K | MAFF | sIL-1Ra/IL-1β | [67] | |
| Metabolic reprogramming |
Breast and lung cancer | R248Q, R273H | - | RhoA, ROCK/GLUT1 translocation/Warburg effect | [68] |
| Head and neck cancer | P151S, G245C, R282W |
AMPK | AMPK inactivation/Warburg effect | [69] |